

ASCO 2004 ABSTRACTS

1. Kitagawa R, Katsumata N, Yamanaka Y, Ando M, Fujiwara Y, Kasamatsu, T, Onda T, Yamada T, Tsunematsu R, Watanabe T. Phase II trial of paclitaxel (T) and carboplatin (C) in patients with recurrent or metastatic cervical carcinoma. ASCO 2004, Abstract no. 5048.
2. Shimizu C, Hasegawa T, Tani Y, Ando M, Katsumata N, Fujiwara Y. Relation between Insulin-like growth factor-1 receptor (IGF-1R) expression and the efficacy of trastuzumab(T) monotherapy for hormone-resistant HER2-positive metastatic breast cancer(MBC). ASCO 2004, Abstract no. 9578.
3. Yamada Y, Yamamoto , Shimoyama T, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Nishioka Y, Yasuda S, Tamura T. A phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. ASCO 2004, Abstract No.2030.
4. Hamaguchi Y, Ohtsu A, Hyodo I, Arai Y, Takiuchi H, Fujii H, Yamaguchi K, Yoshida M, Saito H, Denda T, Koizumi K, Iwase H, Shirao K. A phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine -resistant advanced gastric cancer: The Japan Clinical Oncology Group trial (JCOG0109). ASCO 2004, Abstract No.4071.
5. Ura T, Muro K, Shimada Y, Shirao K, Igaki H, Tashimori Y, Kato H, Ito Y, Imai A, Kagami Y. Definitive chemoradiotherapy may be standard treatment options in clinical stage I esophageal cancer. ASCO 2004, Abstract No.4017.
6. Miyata Y, Shirao K, Ohtsu A, Boku N, Tanigawara Y. Oxaliplatin (L-OHP) in combination with 5-Fluorouracil (5-FU) / l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC): a phase I/II study. ASCO 2004, Abstract No.3705
7. Doi T, Nishida T, Hirota S, Sugiyama T, Yamao K, Yamao K, Koseki M, Okamura T, Shirao K, Ohtsu A. Phase II clinical study of STI571 in Japanese(Jpn) patients (pts) with malignant gastrointestinal stromal tumors(GIST): Results of the B 1201 study. ASCO 2004, Abstract No.4078
8. Tobinai K, Watanabe T, Ogura M, Morishima Y, Itoh K, Igarashi T, Hotta T, Kinoshita T, Matsuno Y, Ohashi Y: Randomized phase II study of concurrent vs sequential combination of rituximab plus CHOP in untreated indolent B-cell non-Hodgkin's lymphoma. ASCO 2004; No. 6577.
9. Ishikura S, Tobinai K, Ohtsu A, Nakamura S, Yoshino T, Takagi T, Tamaki Y, Kinoshita T, Mera K, Yamamoto S, et al.: Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II1, diffuse large B-cell lymphoma of the stomach. ASCO 2004; Abstract No. 6527.
10. Kinoshita T, Hanyu K, Yuge M, Nagai H, Naoe T, Morishima Y, Itoh K, Hotta T, Enami J, Tobinai K. Quantification of minimal residual disease after rituximab with CHOP in indolent B-cell lymphoma: Results of a randomized trial of CHOP combined with concurrent or sequential rituximab. ASCO 2004; Abstract No. 6704.
11. Sekiguchi N, Nishimoto J, Tanimoto K, Ohnishi Y, Watanabe T, Kobayashi Y, Asamura H, Kagami Y, Matsuno Y, Tobinai K: A clinicopathologic study of primary mediastinal large B-cell lymphoma at a single institution in Japan. ASCO 2004; Abstract No. 6686.
12. Ogura M, Kagami Y, Itoh K, Tobinai K, Chou T, Aikawa K, Ishizuka N, Hotta T, Shimoyama M. CHOP therapy is inadequate for low-intermediate risk patients with aggressive non-Hodgkin's lymphoma: Phase II study of CHOP therapy for low or L-I risk aggressive NHL by Japan Clinical Oncology Group (JCOG9508). ASCO 2004; Abstract No. 6703.
13. Okusaka T, Takasaki K, Kasugai H, Furuse J, Sato T, Yamamoto J, for all collaborators. Longitudinal comparisons of results in surgical resection and percutaneous ethanol injection therapy (PEI): Change in treatment strategy for small hepatocellular carcinoma(HCC). ASCO 2004, Abstract No. 4135.
14. Funakoshi A, Okusaka T, Ishii H, Sawaki A, Ohkawa S, Ishikawa O, Saisho S. Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer. ASCO 2004, Abstract No. 4102.
15. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C, Furuse J, Ishii H, Nagase. Phase I study of gemcitabine and S-1 combination therapy in patients with advanced pancreatic cancer. ASCO 2004, Abstract No. 4160.
16. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous-infusion 5-fluorouracil, mitoxantone and cisplatin for metastatic hepatocellular carcinoma. ASCO 2004, Abstract No. 4081.
17. Morizane C, Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Sumi M, Kagami Y, Ikeda H. Phase II trial of chemoradiotherapy using weekly gemcitabine (GEM) in patients (pts) with locally advanced pancreatic cancer (PC). Final results. ASCO 2004, Abstract No. 4192.
18. Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Ohe Y, Tamura T, Negoro S, Ariyoshi Y, Nakagawa K, Fukuoka M. The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). Abstract?No. 7006
19. Gandara DR, Ohe Y, Kubota K, Nishiwaki Y, Ariyoshi Y, Saijo N, Williamson S, Lara PN, Crowley J, Fukuoka M. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials. Abstract?No. 7007
20. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Saijo N, Fukuoka M, Ariyoshi Y. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (final report). Abstract?No. 7206
21. Fujisaka Y, Tamura T, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Horiike A, Kodama T, Saijo N. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients with chemotherapy-induced anemia. Abstract?No. 8206
22. Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S. Adjuvant oral uracil and tegafur (UFT) improves survival after complete mesorectal excision (ME) for pathologic TNM stage III rectal cancer (RC): Results of the National Surgical Adjuvant Study (NSAS)-Colorectal Cancer (CC) 01 randomized trial. ASCO 2004, Abstract No.3524.
23. Sasako M, Sano T, Sairenji M, Arai K, Kinoshita T, Yamamoto S, Ishizuka N. Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG): Left thoraco-abdominal approach (LT) compared with abdominal and transhiatal approach (AT) for cardia or sub-cardia cancer. Results of a surgical randomized controlled trial (JCOG9502). 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) New Orleans, U.S.A., 2004
24. Kawai A, Chuman H, Makimoto A, Ito Y, Yamaguchi U, Morimoto Y, Beppu Y. Ifosfamide-etoposide chemotherapy in patients with advanced adult soft tissue sarcomas. ASCO proceedings 2004; 9062, 829.